CapnoPharm is a profitable biotechnology company active across both the medical device and pharmaceutical segments, generating revenues through B2B and B2C channels. Between 2023 and 2025, the company delivered strong annual growth and achieved two-digit EBIT, reflecting a resilient, scalable business.